PPADS, a purinergic antagonist reduces Fos expression at spinal cord level in a mouse model of mononeuropathy

E. Borsani, R. Albertini, M. Colleoni, P. Sacerdote, A. E. Trovato, C. Lonati, M. Labanca, A. E. Panerai, R. Rezzani, L. F. Rodella

Research output: Contribution to journalArticlepeer-review

Abstract

Recent evidence suggest that ATP plays a role as an endogenous pain mediator generating and/or modulating pain signaling from the periphery to the spinal cord. In this study we evaluated the effects of intraperitoneal administration of P2 receptor antagonist, pyridoxalphosphate-6-azophenyl-2′,4′-disulphonic acid (PPADS), evaluating pain related behaviours and monitoring the expression of Fos, a marker of activated neurons, in an experimental mouse model of neuropathic pain (sciatic nerve tying). The PPADS administration decreased both tactile allodynia and thermal hyperalgesia in a time and dose dependent manner. The dose of 25 mg/kg PPADS completely reversed nociceptive hypersensitivity. Moreover, non-noxious stimulation induced an increase of Fos positive neurons in the spinal cord of animals with tying of sciatic nerve. PPADS administration partially reversed this increase. These results suggest that PPADS reduces neuronal activation at spinal cord level and that P2 receptors are involved in the retrograde signalling progress exciting sensory spinal neurons.

Original languageEnglish
Pages (from-to)74-81
Number of pages8
JournalBrain Research
Volume1199
DOIs
Publication statusPublished - Mar 14 2008

Keywords

  • Fos
  • Neuropathic pain
  • PPADS
  • Purinergic receptor
  • Spinal cord

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Developmental Biology
  • Molecular Biology

Fingerprint Dive into the research topics of 'PPADS, a purinergic antagonist reduces Fos expression at spinal cord level in a mouse model of mononeuropathy'. Together they form a unique fingerprint.

Cite this